Your email has been successfully added to our mailing list.

×
-0.0120442708333333 -0.0120442708333333 -0.0120442708333333 -0.0120442708333333 -0.0110677083333333 -0.0130208333333333 -0.0104166666666666 -0.0120442708333333
Stock impact report

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis [Yahoo! Finance]

KIRIN HLDGS CO LTD S/ADR (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
Company Research Source: Yahoo! Finance
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). Show less Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for KNBWY alerts
Opt-in for
KNBWY alerts

from News Quantified
Opt-in for
KNBWY alerts

from News Quantified